Hepatitis Monthly

Published by: Kowsar

High Prevalence of Q80K Among NS3 Resistance-Associated Substitutions in Subtype 1a Patients with Chronic Hepatitis C Prior to Treatment with Direct Acting Antivirals: The Croatian Data

Ivana Grgic 1 , * , Ana Planinic 1 , Maja Santak 3 , Lana Gorenec 1 , Snjezana Zidovec Lepej 1 and Adriana Vince 2
Authors Information
1 Department for Molecular Diagnostic and Flow Cytometry, University Hospital for Infectious Diseases, Zagreb
2 Department of Viral Hepatitis, University of Zagreb School of Medicine and University Hospital for Infectious Diseases, Zagreb
3 Laboratory for Molecular Biomedicine, Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb
Article information
  • Hepatitis Monthly: May 2017, 17 (5); e45543
  • Published Online: April 26, 2017
  • Article Type: Research Article
  • Received: January 18, 2017
  • Revised: March 20, 2017
  • Accepted: March 22, 2017
  • DOI: 10.5812/hepatmon.45543

To Cite: Grgic I, Planinic A, Santak M, Gorenec L, Lepej S Z, et al. High Prevalence of Q80K Among NS3 Resistance-Associated Substitutions in Subtype 1a Patients with Chronic Hepatitis C Prior to Treatment with Direct Acting Antivirals: The Croatian Data, Hepat Mon. 2017 ; 17(5):e45543. doi: 10.5812/hepatmon.45543.

Copyright © 2017, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014; 59(1): 318-27[DOI][PubMed]
  • 2. Pickett BE, Striker R, Lefkowitz EJ. Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat. 2011; 18(9): 608-18[DOI][PubMed]
  • 3. Vizuete J, Hubbard H, Lawitz E. Next-Generation Regimens: The Future of Hepatitis C Virus Therapy. Clin Liver Dis. 2015; 19(4): 707-16[DOI][PubMed]
  • 4. Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PLoS One. 2015; 10(8)[DOI][PubMed]
  • 5. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014; 384(9941): 403-13[DOI][PubMed]
  • 6. The European Association for the Study of the Liver . EASL recommendations on treatment of hepatitis C .
  • 7. AASLD-IDSA . Recommendations for testing, managing, and treating hepatitis C.
  • 8. Sarrazin C, Lathouwers E, Peeters M, Daems B, Buelens A, Witek J, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015; 116: 10-6[DOI][PubMed]
  • 9. Beloukas A, King S, Childs K, Papadimitropoulos A, Hopkins M, Atkins M, et al. Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK. Clin Microbiol Infect. 2015; 21(11): 1033-9[DOI][PubMed]
  • 10. Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN. Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol. 2015; 65: 50-3[DOI][PubMed]
  • 11. Nguyen LT, Gray E, Dean J, Carr M, Connell J, De Gascun C, et al. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals. Antivir Ther. 2015; 20(8): 865-9[DOI][PubMed]
  • 12. Ruggiero T, Proietti A, Boglione L, Milia MG, Allice T, Burdino E, et al. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naive patients with chronic hepatitis: single-centre experience. Arch Virol. 2015; 160(11): 2881-5[DOI][PubMed]
  • 13. Morel V, Duverlie G, Brochot E. Patients eligible for treatment with simeprevir in a French center. J Clin Virol. 2014; 61(1): 149-51[DOI][PubMed]
  • 14. A high prevalence of Q80K mutation among patients chronically infected with genotype 1 hepatits C virusdue to concurrent circulation of clade I and clade II subtype 1a in Slovenia. ECCMID 2016.
  • 15. Croatian Census 2011.
  • 16. Vilibic-Cavlek T, Kucinar J, Kaic B, Vilibic M, Pandak N, Barbic L, et al. Epidemiology of hepatitis C in Croatia in the European context. World J Gastroenterol. 2015; 21(32): 9476-93[DOI][PubMed]
  • 17. Vince A, Iscic-Bes J, Zidovec Lepej S, Baca-Vrakela I, Bradaric N, Kurelac I, et al. Distribution of hepatitis C virus genotypes in Croatia--a 10 year retrospective study of four geographic regions. Coll Antropol. 2006; 30 Suppl 2: 139-43[PubMed]
  • 18. Croatian reference center for diagnostic and treatment of viral hepatitis: Recomedations for treatment of hepatitis C 2015 .
  • 19. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011; 28(10): 2731-9[DOI][PubMed]
  • 20. Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One. 2012; 7(7)[DOI][PubMed]
  • 21. de Carvalho IM, Alves R, de Souza PA, da Silva EF, Mazo D, Carrilho FJ, et al. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches. J Med Virol. 2014; 86(10): 1714-21[DOI][PubMed]
  • 22. Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology. 2016; 64(2): 360-9[DOI][PubMed]
  • 23. Lieveld FI, Swaans N, Newsum AM, Ho CK, Schinkel J, Molenkamp R, et al. Resistance-associated polymorphisms in Dutch hepatitis C genotype 1a patients with and without HIV infection. Ann Hepatol. 2016; 15(5): 696-704[DOI][PubMed]
  • 24. Vidal LL, Soares MA, Santos AF. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naive subjects. J Viral Hepat. 2016; 23(11): 840-9[DOI][PubMed]
  • 25. Aissa Larousse J, Trimoulet P, Recordon-Pinson P, Papuchon J, Azzouz MM, Ben Mami N, et al. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia. J Med Virol. 2014; 86(8): 1350-9[DOI][PubMed]
  • 26. McCloskey RM, Liang RH, Joy JB, Krajden M, Montaner JS, Harrigan PR, et al. Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism. J Infect Dis. 2015; 211(8): 1288-95[DOI][PubMed]
  • 27. De Luca A, Di Giambenedetto S, Lo Presti A, Sierra S, Prosperi M, Cella E, et al. Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. Open Forum Infect Dis. 2015; 2(2)[DOI][PubMed]
  • 28. Santos AF, Bello G, Vidal LL, Souza SL, Mir D, Soares MA. In-depth phylogenetic analysis of hepatitis C virus subtype 1a and occurrence of 80K and associated polymorphisms in the NS3 protease. Sci Rep. 2016; 6: 31780[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments